RUNDC3A antisense RNA 1 (RUNDC3A-AS1)

RUNDC3A antisense RNA 1 (RUNDC3A-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the RUNDC3A gene. RUNDC3A-AS1 is not a protein-coding gene and is not a classical therapeutic target such as a receptor or enzyme. Instead, it functions at the RNA level, primarily in the cytoplasm, acting as a competing endogenous RNA (ceRNA) that can modulate microRNA activity and thereby regulate expression of other genes. RUNDC3A-AS1 is highly expressed in thyroid cancer tissues and promotes cell proliferation, tumor progression, invasion, and inhibits apoptosis via various miRNA-mediated pathways. For instance, it sponges miR-151b to regulate SNRPB expression[1] and modulates the miR-182-5p/ADAM9 axis promoting metastasis[3]. High expression of RUNDC3A-AS1 is associated with poor prognosis in thyroid cancer patients, and its knockdown reduces tumor cell proliferation and metastatic potential, suggesting it may serve as a molecular biomarker, but not a direct classical drug target[1][3][4]. Notes: - There is currently no evidence of direct drug interaction or drugs targeting RUNDC3A-AS1, nor are there established mechanisms of action for drugs acting on this lncRNA. - It is considered a cancer biomarker, particularly for thyroid cancer[1][3][4], but not a protein or small molecule therapeutic target such as a receptor or enzyme. - No notable safety concerns or therapeutic challenges have been specifically described for targeting RUNDC3A-AS1 itself, as clinical targeting strategies have not yet been established or validated[1][3].